Oncology and Advanced Solid Tumors
Jacobio Pharmaceuticals Co. Ltd. focuses on cancer research in adults with advanced solid tumors, with particular attention to disease settings driven by KRAS G12C mutation.
- Solid tumor oncology
- Relapsed and refractory cancers
- Antitumor activity
The sponsor’s clinical activity includes advanced malignancies across tumor types, reflecting interest in molecularly defined cancers with limited treatment options.
KRAS G12C-Directed Therapeutics
The research portfolio centers on KRAS G12C-mutated cancers, including non-small cell lung cancer and metastatic colorectal cancer, with a therapeutic focus on mutation-specific treatment strategies.
- KRAS-mutant oncology
- NSCLC
- mCRC
Clinical interest extends to both monotherapy and combination approaches in KRAS G12C-positive solid tumors.
Targeted Cancer Therapy
The sponsor is engaged in the development of targeted therapeutic approaches for genetically defined tumors, with attention to precision oncology in advanced disease.
- Mutation-targeted treatment
- Combination oncology regimens
- Treatment-resistant disease
Its research activity reflects a focus on therapies designed for tumors that retain KRAS G12C as a clinically relevant biomarker.
Clinical Safety and Antitumor Evaluation
Jacobio Pharmaceuticals Co. Ltd. also concentrates on safety, tolerability, and early signs of clinical efficacy in patients with advanced cancer.
- Safety and tolerability
- Pharmacokinetics
- Objective response
These areas support its work in evaluating novel anticancer agents for patients with unmet oncologic needs.
